A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Flucytosine (Primary) ; Stem cell therapies (Primary) ; Folinic acid
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions
- 06 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.